Hancock Jaffe Eyes Mid-Year Approval Of ProCol Vascular Bioprosthesis
This article was originally published in The Gray Sheet
Executive Summary
Hancock Jaffe will begin this spring a 180-patient randomized trial of its ProCol prosthetic hemodialysis vascular graft as a replacement for failed native arteriovenous (AV) fistulae